Indications Patients with PM or DM with significant with biopsy-proven PM or DM or NAM who have Indication is qualified to note the muscle weakness unresponsive to significant muscle weakness or dysphagia requirement for muscle biopsy. SWG corticosteroids and other unresponsive to corticosteroids and other reported that there is a small subset of immunosuppressive agents. immunosuppressant agents. patients in whom dysphagia worsens following the introduction of steroids, despite improvement in limb weakness, Patients with IBM who have dysphagia affecting function. who may require 3-6 months of IVIg for resolution of the dysphagia. Patients with rapidly progressive IBM. Qualifying Diagnosis made by a neurologist, with biopsy-proven PM or DM or NAM who have The MRC Sum (12) Score will be used to Criteria rheumatologist or immunologist of: significant muscle weakness or dysphagia assess muscle weakness and determine unresponsive to corticosteroids and other response at review. Video-fluoroscopy will immunosuppressant agents. be used to demonstrate the involvement Patients with PM or DM who have of pharyngeal muscles. significant [Group 1] SWG considered the application of muscle weakness or dysphagia and have disability scales at length - however, there Patients with biopsy-proven PM, DM or not responded to corticosteroids and is no commonly used or validated disability trial NAM scale that can be practically used in the immunosuppressive agents; AND clinic setting for PM/DM– all those OR identified in the literature are research [Group 2] based and too time consuming for use in outpatient clinics. Patients with IBM who have dysphagia
Indications Patients with PM or DM with significant muscle weakness unresponsive to corticosteroids and other immunosuppressive agents. Patients with IBM who have dysphagia affecting function. Patients with rapidly progressive IBM. with biopsy-proven PM or DM or NAM who have significant muscle weakness or dysphagia unresponsive to corticosteroids and other immunosuppressant agents. Indication is qualified to note the requirement for muscle biopsy. SWG reported that there is a small subset of patients in whom dysphagia worsens following the introduction of steroids, despite improvement in limb weakness, who may require 3-6 months of IVIg for resolution of the dysphagia. Qualifying Criteria Diagnosis made by a neurologist, rheumatologist or immunologist of: Patients with PM or DM who have significant muscle weakness or dysphagia and have not responded to corticosteroids and immunosuppressive agents; OR Patients with IBM who have dysphagia with biopsy-proven PM or DM or NAM who have significant muscle weakness or dysphagia unresponsive to corticosteroids and other immunosuppressant agents. [Group 1] Patients with biopsy-proven PM, DM or NAM AND [Group 2] The MRC Sum (12) Score will be used to assess muscle weakness and determine response at review. Video-fluoroscopy will be used to demonstrate the involvement of pharyngeal muscles. SWG considered the application of disability scales at length - however, there is no commonly used or validated disability scale that can be practically used in the clinic setting for PM/DM– all those identified in the literature are research based and too time consuming for use in outpatient clinics. trial
inflammatory-myopathies-polymyositis%28pm%29-dermatomyositis%28dm%29-and-necrotising-autoimmune-myopathy%28nam%29.DOCX